gabab

(E)-GABAB receptor antagonist 1 is a trans-GABAB receptor antagonist that decreases GABA-induced IP3 (inositol trisphosphate) production with an IC50 of 37.9 μM. It is a selective and negative allosteric modulator of GABAB (γ-Aminobutyric acid) receptors.

(E)-GABAB receptor antagonist 1 decreases GABA-induced IP3 (inositol trisphosphate) production with IC50 of 37.9 μM.GABAB receptor antagonist 1 is a selective and negative allosteric modulator of GABAB (γ-Aminobutyric acid) receptors.

(R)-baclofen (STX209), a derivative of gamma-aminobutyric acid, is commonly utilized for the treatment of spasticity.

Phenibut (Aminophenylbutyric acid) is a central depressant and derivative of the naturally occurring inhibitory neurotransmitter γ-aminobutyric acid (GABA).

γ-Aminobutyric acid (4-Aminobutyric acid) is the predominant inhibitory neurotransmitter in the central nervous system.

Phosphorylethanolamine (O-Phosphorylethanolamine) is a phosphomonoester metabolite of the phospholipid metabolism. Phosphorylethanolamine is a precursor of phospholipid synthesis and a product of phospholipid breakdown. Phosphomonoesters are present at much higher levels in the brain than in other organs. In developing the brain, phosphomonoesters are normally elevated during the period of neuritic proliferation. This also coincides with the occurrence of normal programmed cell death and synaptic pruning in developing the brain. These findings are consistent with the role of phosphomonoesters in membrane biosynthesis. Phosphorylethanolamine shows a strong structural similarity to the inhibitory neurotransmitter, GABA, and the GABAB receptor partial agonist, 3-amino-propylphosphonic acid. Phosphorylethanolamine is a phosphomonoester which is decreased in post-mortem Alzheimer's disease (AD) brain.

Inaperisone is a novel centrally acting muscle relaxant that inhibits the voiding reflex. Inaperisone may inhibit the voiding reflex by acting indirectly on GABAB receptors in the brainstem.

Saclofen is a sulfonic analog of the inhibitory neurotransmitter γ-aminobutyric acid (GABA) that acts as a competitive antagonist of the GABAB receptor (IC50: 7.8 μM).1 This compound can be used to determine the functional roles for the GABAB receptor as

3-aminopropylphosphonic acid (3-APPA) is a phosphonic analog of GABA that acts as a partial agonist of GABAB receptors (IC50 = 1.5 μM in a radioligand binding assay).

rac-BHFF ((R,S)-BHFF) is potent and selective GABA B receptor positive allosteric modulator that increases the potency and efficacy of GABA ( > 15-fold and > 149% respectively). It exhibits anxiolytic activity in vivo and is orally active.

SSD114 is a novel GABAB receptor positive allosteric modulator.

CGP52432 is a very potent antagonist of GABAB receptors (IC50 = 85 nM).

SCH-50910 is an antagonist of GABAB receptor.

CGP 47656 is an agonist of GABAB receptor.

BHF-177 is a positive allosteric modulator of the GABAB receptor. BHF-177 reduces self-administration of nicotine in animal studies.

SCH 50911 is (+)-(S)-5,5-dimethylmorpholinyl-2-acetic acid and is a selective, orally-active and competitive γ-Aminobutyric acid B GABA(B) receptor antagonist, binds to GABA(B) receptor (IC50: 1.1 μM). SCH 50911 antagonizes GABA(B) autoreceptors, increasi

Lesogaberan is an effective and selective GABAB receptor agonist (EC50: 8.6 nM for human recombinant GABAB receptors). For rat brain GABAB and GABAA receptors, the binding affinity (Kis) is 5.1 nM and 1.4 μM, respectively.

GABAB agonist

CGP 71872 is an agonist of GABAB receptor.

Valiloxibic acid is a prodrug of γ-Hydroxybutyric acid (GHB).GHB is a naturally occurring neurotransmitter and a psychoactive drug, it acts on the GHB receptor and is a weak agonist at the GABAB receptor.

CGP36216 hydrochloride acts as a selective antagonist at the presynaptic GABA receptor, specifically binding to the GABAB receptor with a Ki value of 0.3 μM. This compound is leveraged in research focused on anxiety and trauma-related disorders [1] [2].

Muscimol hydrochloride (Agarin; Agarine) is an isoxazole compound known for its psychoactive properties, acting as a potent selective agonist of GABA A receptors (EC 50=0.2 μM) and a partial agonist of GABA C receptors, while exhibiting inactivity at GABA B receptors. Derived from Amanita muscaria and related mushroom species, it exerts calming, anti-anxiety, and hallucinatory effects [1].

α-Conotoxin PeIA is an analgesic that inhibits nAChRs α6β4, α9α10, and α3β2, and potently inhibits the N-type calcium channel through GABAB receptor activation [1] [2] [3].

Phaclofen (3-Amino-2-(4-chlorophenyl)propanephosphonic acid) is a selective GABAB receptor antagonist, which can partially antagonize the sedative effect of (-)-baclofen, and reversibly antagonize the inhibition of cholinergic convulsive response of guinea pig ileum and distal colon by baclofen or GABA. Inhibits the cholinergic convulsive response in the guinea pig ileum and distal colon by baclofen or GABA.

4-Aminobutyric acid-2,2,3,3,4,4-d6 is a deuterated compound of 4-Aminobutyric acid. 4-Aminobutyric acid has a CAS number of 56-12-2. 4-Aminobutyric acid is the most common inhibitory neurotransmitter in the central nervous system.

CGP 44532 a GABAB receptor agonist.

CGP 55845 is a potent, selective GABAB receptor antagonist (IC50 = 5 nM) that prevents agonist binding (pKi = 8.35) and inhibits GABA and glutamate release (pEC50 values are 8.08 and 7.85 respectively).

ADX71441 is a GABAB positive allosteric modulator (PAM). ADX71441 increases urinary latencies and reduces the number of urinary events and the total and average urinary volumes. ADX71441 may also mitigate alcoholism and have analgesic effects in the bladd

4-Fluorophenibut (developmental code name CGP-11130; also known as β-(4-fluorophenyl)-γ-aminobutyric acid or β-(4-fluorophenyl)-GABA) is a GABAB receptor agonist which was never marketed. It is selective for the GABAB receptor over the GABAA receptor (IC50 = 1.70 μM and > 100 μM, respectively). The drug is a GABA analogue and is closely related to baclofen (β-(4-chlorophenyl)-GABA), tolibut (β-(4-methylphenyl)-GABA), and phenibut (β-phenyl-GABA). It is less potent as a GABAB receptor agonist than baclofen but more potent than phenibut.

2-Hydroxysaclofen is a GABAB receptor antagonist.

CGP 35348 is a selective antagonist of GABAB receptor (EC50 = 34 μM). CGP 35348 can be used in studies of neuromuscular coordination and spatial learning after neonatal brain damage in albino mice.

CGP 36216 hydrochloride is a potent and selective antagonist of GABAB receptors (IC50: 43 µM).

CGP-54626 is a selective antagonist of the GABAB receptor (IC50 = 4 nM ).

CGP55845 hydrochloride is a potent and selective GABAB receptor antagonist with an IC50 of 6 nM, suitable for use in neurological research [1] [2].

(R)-4-Amino-3-hydroxybutyric acid, also known as (R)-GABOB, acts as a modulator of GABA receptors, specifically binding to both GABAA and GABAB receptors and blocking GABA reuptake in rat brain synaptosomes. Additionally, it serves as a GABAC receptor agonist, triggering currents in patch-clamp assays with Xenopus oocytes that express the human receptor. In vivo studies reveal its capability to suppress electrical discharges in the amygdala in cats undergoing N-amidinobenzamide-triggered seizures, indicating its potential therapeutic application in managing seizure disorders.

GABAB receptor agonist

Lesogaberan (AZD-3355) hydrochloride is a potent and selective GABA B receptor agonist with an EC 50 of 8.6 nM for human recombinant GABA B receptor. The affinity ( K i s) of Lesogaberan hydrochloride for rat GABA B and GABA A receptors, as measured by displacement of GABA binding in brain membranes: 5.1 nM and 1.4 μM, respectively. Lesogaberan hydrochloride inhibits transient lower esophageal sphincter relaxation through a peripheral mode of action .

CGP 62349 is an antagonist of GABAB receptor.

Phenibut hydrochloride (3-Amino-4-phenylbutyric acid hydrochloride) is a GABA mimetic that acts as an agonist at GABAB receptors, blocks α2δ subunit-containing voltage-gated calcium channels, stimulates dopamine receptors, and inhibits the actions of β-phenethylamine

CGP 36742 is a selective antagonist of the GABAB receptor that can penetrate the blood-brain barrier after peripheral administration (IC50: 32 μM). It is useful in the treatment of depression.

Positive allosteric modulator of GABAB receptors

CGP 54626 hydrochloride is a GABAB receptor antagonist.

CGP 46381 is a GABAB receptor antagonist.

COR659 is a GABAB positive allosteric modulator (PAM) . COR659 suppresses alcohol and chocolate self-administration in rats[1]. COR659 apparently exerts its effects via a composite mechanism, including positive allosteric modulation of the GABAB receptor and an action at the cannabinoid CB1 receptor[3]. COR659 (0, 2.5, 5 and 10 mg kg) treatment is completely ineffective on lever-responding (FR10) for regular food pellets in food-deprived Wistar rats[1].COR659 is able to suppress lever-responding for a sucrose solution in sP rats and a chocolate solution in Wistar rats[2]. Animal Model: Male sP and Wistar rats[1]. [1]. Paola Maccioni, et al. Suppressing effect of COR659 on alcohol, sucrose, and chocolate self-administration in rats: involvement of the GABA B and cannabinoid CB 1 receptors. Psychopharmacology (Berl). 2017 Sep;234(17):2525-2543. [2]. Francesca Ferlenghi, et al. The GABA B receptor positive allosteric modulator COR659: In vitro metabolism, in vivo pharmacokinetics in rats, synthesis and pharmacological characterization of metabolically protected derivatives. Eur J Pharm Sci. 2020 Dec 1;155:105544. [3]. Paola Maccioni, et al. Anti-addictive properties of COR659 - Additional pharmacological evidence and comparison with a series of novel analogues. Alcohol. 2019 Mar;75:55-66.

CGP 64213 is a GABAb receptor agonist.

Lesogaberan (AZD-3355) napadisylate is a potent and selective agonist of GABA B receptors, with an EC50 of 8.6 nM for human recombinant GABA B receptors. It has an affinity (Ki) of 5.1 nM for rat GABA B receptors and 1.4 μM for GABA A receptors, determined by displacement of [3H]GABA binding in brain membranes. Lesogaberan napadisylate exerts a peripheral mode of action, inhibiting transient lower esophageal sphincter relaxation.